Drug Trials Snapshot: EXKIVITY (mobocertinib)

Drug Trials Snapshot: EXKIVITY (mobocertinib) EXKIVITY is a kinase inhibitor used to treat adult patients with a type of lung cancer (non-small cell lung cancer or NSCLC) which: has a specific gene mutation (EGFR exon 20 insertion mutations) and, is locally advanced or has spread to other parts of the body (metastatic) and, has progressed on or after platinum-based chemotherapy. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-exkivity